Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study

Julia Hippisley-Cox, Carol Coupland, Peter Brindle, Julia Hippisley-Cox, Carol Coupland, Peter Brindle

Abstract

Objectives To develop and validate updated QRISK3 prediction algorithms to estimate the 10 year risk of cardiovascular disease in women and men accounting for potential new risk factors.Design Prospective open cohort study.Setting General practices in England providing data for the QResearch database.Participants 1309 QResearch general practices in England: 981 practices were used to develop the scores and a separate set of 328 practices were used to validate the scores. 7.89 million patients aged 25-84 years were in the derivation cohort and 2.67 million patients in the validation cohort. Patients were free of cardiovascular disease and not prescribed statins at baseline.Methods Cox proportional hazards models in the derivation cohort to derive separate risk equations in men and women for evaluation at 10 years. Risk factors considered included those already in QRISK2 (age, ethnicity, deprivation, systolic blood pressure, body mass index, total cholesterol: high density lipoprotein cholesterol ratio, smoking, family history of coronary heart disease in a first degree relative aged less than 60 years, type 1 diabetes, type 2 diabetes, treated hypertension, rheumatoid arthritis, atrial fibrillation, chronic kidney disease (stage 4 or 5)) and new risk factors (chronic kidney disease (stage 3, 4, or 5), a measure of systolic blood pressure variability (standard deviation of repeated measures), migraine, corticosteroids, systemic lupus erythematosus (SLE), atypical antipsychotics, severe mental illness, and HIV/AIDs). We also considered erectile dysfunction diagnosis or treatment in men. Measures of calibration and discrimination were determined in the validation cohort for men and women separately and for individual subgroups by age group, ethnicity, and baseline disease status.Main outcome measures Incident cardiovascular disease recorded on any of the following three linked data sources: general practice, mortality, or hospital admission records.Results 363 565 incident cases of cardiovascular disease were identified in the derivation cohort during follow-up arising from 50.8 million person years of observation. All new risk factors considered met the model inclusion criteria except for HIV/AIDS, which was not statistically significant. The models had good calibration and high levels of explained variation and discrimination. In women, the algorithm explained 59.6% of the variation in time to diagnosis of cardiovascular disease (R2, with higher values indicating more variation), and the D statistic was 2.48 and Harrell's C statistic was 0.88 (both measures of discrimination, with higher values indicating better discrimination). The corresponding values for men were 54.8%, 2.26, and 0.86. Overall performance of the updated QRISK3 algorithms was similar to the QRISK2 algorithms.Conclusion Updated QRISK3 risk prediction models were developed and validated. The inclusion of additional clinical variables in QRISK3 (chronic kidney disease, a measure of systolic blood pressure variability (standard deviation of repeated measures), migraine, corticosteroids, SLE, atypical antipsychotics, severe mental illness, and erectile dysfunction) can help enable doctors to identify those at most risk of heart disease and stroke.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: JHC is professor of clinical epidemiology at the University of Nottingham and codirector of QResearch a not-for-profit organisation that is a joint partnership between the University of Nottingham and Egton Medical Information Systems (leading commercial supplier of IT for 55% of general practices in the UK). JHC is also a paid director of ClinRisk, which produces open and closed source software to ensure the reliable and updatable implementation of clinical risk algorithms within clinical computer systems to help improve patient care. CC is associate professor of medical statistics at the University of Nottingham and a paid consultant statistician for ClinRisk. PB is partly funded by Health Research Collaboration for Leadership in Applied Health Research and Care West (NIHR CLAHRC West), Bristol Clinical Commissioning Group and the West of England Academic Health Science Network.. This work and any views expressed within it are solely those of the authors and not of any affiliated bodies or organisations.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5441081/bin/hipj036510.f1.jpg
Fig 1 Funnel plots of discrimination performance (Harrell’s C statistic) across 328 general practices
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5441081/bin/hipj036510.f2.jpg
Fig 2 Predicted and observed 10 year cardiovascular disease risk by 10th of predicted risk
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5441081/bin/hipj036510.f3.jpg
Fig 3 10 year risk of 22.5% based on model C for a white man, aged 44, heavy smoker, total cholesterol: high density lipoprotein (HDL) cholesterol ratio of 2, systolic blood pressure of 132 mm Hg, standard deviation of systolic blood pressure of 10 mm Hg, body mass index of 31.22, atrial fibrillation, erectile dysfunction, migraine, and steroid use
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5441081/bin/hipj036510.f4.jpg
Fig 4 10 year risk ratio of 7.5% based on model C for white man, aged 44, heavy smoker, total cholesterol: high density lipoprotein cholesterol ratio of 2, systolic blood pressure of 132 mm Hg, standard deviation of systolic blood pressure of 0, body mass index of 31.22, migraine, steroid use, no atrial fibrillation, and no erectile dysfunction

References

    1. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007;335:136 10.1136/bmj.39261.471806.55. .
    1. Hippisley-Cox J, Coupland C. QRISK2. Annual Update Information 2016;2016:5.
    1. Hippisley-Cox J. Validity and completeness of the NHS Number in primary and secondary care electronic data in England 1991-2013. 2013; 1. Hippisley-Cox J. Validity and completeness of the NHS number in primary and secondary care: electronic data in England 1991-2013 (accessed June 2013).
    1. Hippisley-Cox J, Coupland C, Brindle P. The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open 2014;4:e005809 10.1136/bmjopen-2014-005809 .
    1. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ 2009;339:b2584 10.1136/bmj.b2584 .
    1. Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 2010;340:c2442 10.1136/bmj.c2442 .
    1. Collins GS, Altman DG. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ 2012;344:e4181 10.1136/bmj.e4181 .
    1. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 2008;94:34-9. 10.1136/hrt.2007.134890 .
    1. Riley RD, Ensor J, Snell KIE, et al. External validation of clinical prediction models using big datasets from e-health records or IPD meta-analysis: opportunities and challenges. BMJ 2016;353:i3140 10.1136/bmj.i3140 .
    1. Morris RW, Cooper JA, Shah T, et al. UCLEB Consortium. Marginal role for 53 common genetic variants in cardiovascular disease prediction. Heart 2016;102:1640-7. 10.1136/heartjnl-2016-309298 .
    1. Tillin T, Hughes AD, Whincup P, et al. SABRE Study Group. Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE--Southall And Brent REvisited). Heart 2014;100:60-7. 10.1136/heartjnl-2013-304474. .
    1. Schofield P, Crichton N, Chen R. Methods for assessing cardiovascular disease risk in a UK black population. Heart 2012;98:1373-7. 10.1136/heartjnl-2012-302168 .
    1. Arts EEA, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015;74:668-74. 10.1136/annrheumdis-2013-204024 .
    1. Pike MM, Decker PA, Larson NB, et al. Improvement in Cardiovascular Risk Prediction with Electronic Health Records. J Cardiovasc Transl Res 2016;9:214-22. 10.1007/s12265-016-9687-z .
    1. Robson J, Dostal I, Sheikh A, et al. The NHS Health Check in England: an evaluation of the first 4 years. BMJ Open 2016;6:e008840 10.1136/bmjopen-2015-008840 .
    1. Crossan C, Lord J, Ryan R, et al. Cost effectiveness of case-finding strategies for primary prevention of cardiovascular disease: a modelling study. Br J Gen Pract 2017;67:e67-77. 10.3399/bjgp16X687973 .
    1. Dixon P, Hollinghurst S, Ara R, Edwards L, Foster A, Salisbury C. Cost-effectiveness modelling of telehealth for patients with raised cardiovascular disease risk: evidence from a cohort simulation conducted alongside the Healthlines randomised controlled trial. BMJ Open 2016;6:e012355 10.1136/bmjopen-2016-012355 .
    1. Salisbury C, O’Cathain A, Thomas C, et al. Telehealth for patients at high risk of cardiovascular disease: pragmatic randomised controlled trial. BMJ 2016;353:i2647 10.1136/bmj.i2647 .
    1. Excellence NIfC. Quality and outcomes framework (QOF) indicator guidance: primary prevention of cardiovascular disease London 2011. accessed 05.06.2013 2013.
    1. National Clinical Guideline Centre. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2014: 286.
    1. Department of Health. NHS Health Check: Vascular Risk Assessment and Management Best Practice Guidance. In: Department of Health, ed. London, 2009.
    1. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002. 10.1001/jama.294.23.2996 .
    1. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013;6:99-109. 10.1161/CIRCOUTCOMES.112.966903 .
    1. Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013;381:153-65. 10.1016/S0140-6736(12)60520-0 .
    1. Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 2016;353:i2610 10.1136/bmj.i2610 .
    1. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905. 10.1016/S0140-6736(10)60308-X .
    1. Hippisley-Cox J, Coupland C. Predicting risk of emergency admission to hospital using primary care data: derivation and validation of QAdmissions score. BMJ Open 2013;3:e003482 10.1136/bmjopen-2013-003482 .
    1. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82. 10.1136/bmj.39609.449676.25. .
    1. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods 2002;7:147-77. 10.1037/1082-989X.7.2.147 .
    1. Group TAM. The Academic Medicine Group. Academic medicine: problems and solutions. BMJ 1989;298:573-9. 10.1136/bmj.298.6673.573 .
    1. Steyerberg EW, van Veen M. Imputation is beneficial for handling missing data in predictive models. J Clin Epidemiol 2007;60:979 10.1016/j.jclinepi.2007.03.003 .
    1. Moons KGM, Donders RART, Stijnen T, Harrell FE Jr. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol 2006;59:1092-101. 10.1016/j.jclinepi.2006.01.009 .
    1. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3-15. 10.1177/096228029900800102 .
    1. Rubin DB. Multiple Imputation for Non-response in Surveys.John Wiley, 1987. 10.1002/9780470316696.
    1. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999;28:964-74. 10.1093/ije/28.5.964 .
    1. Hosmer D, Lemeshow S. Applied Logistic Regression.John Wiley, 1989.
    1. Royston P. Explained variation for survival models. Stata J 2006;6:1-14.
    1. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004;23:723-48. 10.1002/sim.1621 .
    1. Harrell FE Jr, , Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>;2-4 .
    1. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015;162:55-63. 10.7326/M14-0697 .
    1. Burch RC, Rayhill ML. Migraine and vascular disease. BMJ 2016;353:i2806 10.1136/bmj.i2806 .
    1. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA 2006;296:283-91. 10.1001/jama.296.3.283 .
    1. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914 10.1136/bmj.b3914 .
    1. Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Saf 2007;16:882-90. 10.1002/pds.1424 .
    1. Fardet L, Petersen I, Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing’s syndrome: cohort study. BMJ 2012;345:e4928 10.1136/bmj.e4928. .
    1. Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis 2007;192:376-83. 10.1016/j.atherosclerosis.2006.05.019 .
    1. Foguet-Boreu Q, Fernandez San Martin MI, Flores Mateo G, et al. Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysis. BMC Psychiatry 2016;16:141 10.1186/s12888-016-0833-6 .
    1. McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol 2011;7:227-41. 10.1586/eci.10.98 .
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305. 10.1056/NEJMoa041031 .
    1. Stevens SL, Wood S, Koshiaris C, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ 2016;354:i4098 10.1136/bmj.i4098 .
    1. Hata J, Arima H, Rothwell PM, et al. ADVANCE Collaborative Group. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation 2013;128:1325-34. 10.1161/CIRCULATIONAHA.113.002717 .
    1. Feinstein MJ. Cardiovascular disease risk assessment in HIV: navigating data-sparse zones. Heart 2016;102:1157-8. 10.1136/heartjnl-2016-309752 .
    1. Kingery JR, Alfred Y, Smart LR, et al. Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania. Heart 2016;102:1200-5. 10.1136/heartjnl-2015-309026 .
    1. Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009;338:b880 10.1136/bmj.b880. .
    1. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 2012;344:e3427 10.1136/bmj.e3427. .
    1. Hippisley-Cox J, Coupland C. Predicting the risk of chronic Kidney Disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores. BMC Fam Pract 2010;11:49 10.1186/1471-2296-11-49 .
    1. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ 2011;343:d4656 10.1136/bmj.d4656 .
    1. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009;339:b4229 10.1136/bmj.b4229 .
    1. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ 2011;342:d3651 10.1136/bmj.d3651 .
    1. Collins GS, Altman DG. External validation of QDSCORE(®) for predicting the 10-year risk of developing Type 2 diabetes. Diabet Med 2011;28:599-607. 10.1111/j.1464-5491.2011.03237.x .
    1. Majeed A. Sources, uses, strengths and limitations of data collected in primary care in England. Health Stat Q 2004;(21):5-14..

Source: PubMed

3
Abonnieren